FOXC2 promotes colorectal cancer metastasis by directly targeting MET

Oncogene

Volumn 34, Issue 33, 2015, Pages 4379-4390

  Cui, Y M ^a   Jiao, H L ^a   Ye, Y P ^a   Chen, C M ^a   Wang, J X ^a   Tang, N ^a   Li, T T ^a   Lin, J ^a   Qi, L ^a   Wu, P ^a   Wang, S Y ^a   He, M R ^a   Liang, L ^a   Bian, X W ^b   Liao, W T ^a   Ding, Y Q ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CATENIN; NERVE CELL ADHESION MOLECULE; PROTEIN P120; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR FOXC2; UVOMORULIN; VIMENTIN; FORKHEAD TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER STAGING; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; METASTASIS; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; COLORECTAL NEOPLASMS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84939568163     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.368     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Van Cutsem E, Grothey A. Regorafenib for metastatic colorectal cancer-authors' reply. Lancet 2013; 381: 1538-1539.
3. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43: 1348-1360.
4. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. New Engl J Med 2009; 361: 2449-2460.
5. Hayashi H, Sano H, Seo S, Kume T. The Foxc2 transcription factor regulates angiogenesis via induction of integrin beta3 expression. J Biol Chem 2008; 283: 23791-23800.
6. Kume T. The role of FoxC2 transcription factor in tumor angiogenesis. J Oncol 2012; 2012: 204593.
7. Sano H, Leboeuf JP, Novitskiy SV, Seo S, Zaja-Milatovic S, Dikov MM et al. The Foxc2 transcription factor regulates tumor angiogenesis. Biochem Biophys Res Commun 2010; 392: 201-206.
8. Mani SA, Yang J, Brooks M, Schwaninger G, Zhou A, Miura N et al. Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci USA 2007; 104: 10069-10074.
9. Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. Cancer Res 2013; 73: 1981-1992.
10. Nishida N, Mimori K, Yokobori T, Sudo T, Tanaka F, Shibata K et al. FOXC2 is a novel prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol 2011; 18: 535-542.
11. Zhu JL, Song YX, Wang ZN, Gao P, Wang MX, Dong YL et al. The clinical significance of mesenchyme forkhead 1 (FoxC2) in gastric carcinoma. Histopathology 2013; 62: 1038-1048.
12. Jiang W, Pang XG, Wang Q, Shen YX, Chen XK, Xi JJ. Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection. Clin Lung Cancer 2012; 13: 280-287.
13. Yu YH, Chen HA, Chen PS, Cheng YJ, Hsu WH, Chang YW et al. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene 2013; 32: 431-443.
14. Mortazavi F, An J, Dubinett S, Rettig M. p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells. Mol Cancer Res 2010; 8: 762-774.
15. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274-284.
16. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-292.
17. Xue Y, Cao R, Nilsson D, Chen S, Westergren R, Hedlund EM et al. FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc Natl Acad Sci USA 2008; 105: 10167-10172.
18. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1: 147-154.
19. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-925.
20. Sattler M, Salgia R. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep 2007; 9: 102-108.
21. Mazzone M, Comoglio PM. The Met pathway: master switch and drug target in cancer progression. FASEB J 2006; 20: 1611-1621.
22. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF et al. Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 1991; 251: 802-804.
23. Chmielowiec J, Borowiak M, Morkel M, Stradal T, Munz B, Werner S et al. c-Met is essential for wound healing in the skin. J Cell Biol 2007; 177: 151-162.
24. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002; 109: 863-867.
25. De Oliveira AT, Matos D, Logullo AF, DA Silva SR, Neto RA, Filho AL et al. MET Is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 2009; 29: 4807-4811.
26. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003; 9: 1480-1488.
27. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007; 248: 219-228.
28. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene 1992; 7: 181-185.
29. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A et al. c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008; 265: 258-269.
30. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer cell 2003; 3: 347-361.
31. Boon EM, van der Neut R, van de Wetering M, Clevers H, Pals ST. Wnt signaling regulates expression of the receptor tyrosine kinase met in colorectal cancer. Cancer Res 2002; 62: 5126-5128.
32. Rasola A, Fassetta M, De Bacco F, D'Alessandro L, Gramaglia D, Di Renzo MF et al. A positive feedback loop between hepatocyte growth factor receptor and betacatenin sustains colorectal cancer cell invasive growth. Oncogene 2007; 26: 1078-1087.
33. Stein U, Clinical Schlag PM. biological, and molecular aspects of metastasis in colorectal cancer. Recent Results Cancer Res 2007; 176: 61-80.
34. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009; 15: 59-67.
35. Liu Y. The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization. Gene 1998; 215: 159-169.
36. Liang H, O'Reilly S, Liu Y, Abounader R, Laterra J, Maher VM et al. Sp1 regulates expression of MET, and ribozyme-induced down-regulation of MET in fibrosarcoma-derived human cells reduces or eliminates their tumorigenicity. Int J Oncol 2004; 24: 1057-1067.
37. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008; 17: 997-1011.
38. Zhang SH, Wang CJ, Shi L, Li XH, Zhou J, Song LB et al. High Expression of FLOT1 is associated with progression and poor prognosis in hepatocellular carcinoma. PLoS ONE 2013; 8: e64709.
39. Park SJ, Gadi J, Cho KW, Kim KJ, Kim SH, Jung HS et al. The forkhead transcription factor Foxc2 promotes osteoblastogenesis via up-regulation of integrin beta1 expression. Bone 2011; 49: 428-438.
40. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006; 66: 6225-6232.
41. Liao WT, Jiang D, Yuan J, Cui YM, Shi XW, Chen CM et al. HOXB7 as a prognostic factor and mediator of colorectal cancer progression. Clin Cancer Res 2011; 17: 3569-3578.
42. Shibue T, Brooks MW, Inan MF, Reinhardt F, Weinberg RA. The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov 2012; 2: 706-721.
43. Tseng W, Leong X, Engleman E. Orthotopic mouse model of colorectal cancer. J Vis Exp 2007; 10: 484.